You Searched For: Van Der Voort Lucht en Milieu Amste

Supplier: Adipogen

Description: Activation of cells by LPS is mediated by the Toll-like receptor 4 (TLR4). For optimal interaction with LPS, TLR4 requires association with myeloid differentiation protein 2 (MD-2). According to current consensus activation of TLR4 is preceded by the transfer of LPS to membrane-bound (m) or soluble (s) CD14 by LPS-binding protein (LBP). Re-form LPS and lipid A, but not S-form LPS, are capable of inducing TNF-alpha responses also in the absence of CD14. LPS, synthesized by most wild-type (WT) Gram-negative bacteria (S-form LPS), consists of three regions, the O-polysaccharide chain, which is made up of repeating oligosaccharide units, the core oligosaccharide and the lipid A, which harbors the endotoxic activity of the entire molecule. R-form LPS synthesized by the so-called rough (R) mutants of Gram-negative bacteria lacks the O-specific chain. Furthermore, the core-oligosaccharide may be present in different degrees of completion, depending on the class (Ra to Re) to which the mutant belongs. LPS are amphipathic molecules whose hydrophobicity decreases with increasing length of the sugar part. Based upon these differences, S- and R-form LPS show marked differences in the kinetics of their blood clearance and cellular uptake as well as in the ability to induce oxidative burst in human granulocytes and to activate the host complement system.

Supplier: Adipogen

Description: gamma-Rubromycin is a HIV-1 reverse transcriptase and human telomerase inhibitor.

Supplier: Adipogen

Description: Building block for synthesis.

Catalog Number: (102981-508)

Supplier: Adipogen

Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

Sale

Supplier: Adipogen

Description: Inhibitor of pan-Trk activity (IC(50) = 8 and 12nM for TrkA and TrkB). Shown to target Trk (tropomyosin receptor kinase) ATP binding cleft and an immediately adjacent hydrophobic pocket. Preferentially arrests the proliferation of Ba/F3 cells fused with Tel-TrkA, Tel-TrkB and Tel-TrkC (IC(50) = 11, 9 and 7nM, respectively) and in Ba/F3 and RIE cells expressing both TrkA and NGF (IC(50) = 42 and 17nM, respectively) over Mo7e-c-Kit and Rat-A10-PDGFR (IC(50) = 1 and 0.5µM) and Ba/F3-Tel-KDR and wt-Ba/F3 cells (IC(50) = 3.0 and 5.6µM). Displays ~100-fold greater selectivity among a panel of 59 closely related kinases and in 33 cellular kinase assays. Weakly active against relevant cytochrome P450 isozymes and hERG channel, and exhibit adequate microsomal stability, pharmacokinetic profile and efficacy in mice and rats. Suppresses tumor growth in a mouse RIE-TrkAmNGF xenograft model (50mg/kg, p.o.).

Supplier: Adipogen

Description: Linifanib (A 741439; A-741439; A741439; ABT-869; ABT869; RG3635) is an orally active multi-targeted receptor tyrosine kinase inhibitor for the treatment of various cancers. The compound is designed to inhibit vascular endothelial growth factor and platelet-derived growth factor receptors and is a multitargeted tyrosine kinase receptor inhibitor that suppresses FLT3 signaling. It is in phase III development for liver cancer and phase II development for non-small cell lung cancer, breast cancer, and colorectal cancer. Recent research also indicates that Linifanib inhibits proliferation and induces apoptosis in AML patient cells via reduction of AKT and GSK3beta phosphorylation and maybe influencial in AML therapy.

Supplier: Adipogen

Description: MK-2206 is a highly selective inhibitor of Akt1, Akt2 and Akt3 with IC(50) of 8nM, 12nM and 65nM, respectively.

Supplier: Adipogen

Description: CC-401 is a competitive inhibitor of the ATP binding site in the active, phosphorylated, form of JNK. This prevents JNK from phosphorylating its various target molecules, including the amino terminus of c-Jun. It is a potent inhibitor of all three forms of JNK (Ki of 25-50 nM), and has at least 40-fold selectivity for JNK compared with other related kinases, including: p38, ERK, IKK2, PKC, Lck, and ZAP70. CC-401 acts to inhibit JNK signaling by competitive binding to the adenosine triphosphate-binding site in the active, phosphorylated, form of JNK, resulting in inhibition of the phosphorylation of JNK targets, such as the amino-terminal activation domain of the transcription factor, c-Jun. In cell-based assays, 1-5 muM CC-401 provides specific JNK inhibition.

Supplier: Adipogen

Description: Off-white powder

Supplier: Adipogen

Description: 6-TET is an amino-conjugatable fluorescent probe that is widely used in nucleic acid sequencing and related research. It can also be used to label peptides and oligonucleotides.

Supplier: Adipogen

Description: Unmethylated CG dinucleotides within particular sequence contexts are responsible for the immunostimulatory activity of bacterial DNA. Synthetic oligonucleotides (ODN) that contain such CpG motifs (CpG ODNs) mimic microbial DNA. The innate immune system of vertebrates has the ability to recognize CpG motifs in microbial DNA via the Toll-like receptor (TLR) 9 if the CpG ODN were free of additional immune stimulatory contaminants often present in synthetic commercial CpG ODN preparations designed for molecular biology applications (i.e. PCR). Given that high quality CpG ODNs were used, a close link has been established between the expression of TLR9 on certain immune cell subsets and the modulation of the immune system by CpG DNA. Different types of CpG ODNs were identified based on their differing biological effects on different cell types: ODN Type A is a potent inducer of IFN-alpha in human PDC, (i.e. ODN 1585 or 2216) leading to antigen presenting cell (APC) maturation, whereas ODN Type B (i.e. ODN 2006 or ODN 1668 / ODN 1826) is a weak inducer of IFN-alpha but rather stimulates IL-8 production and increasing costimulatory and Ag-presenting molecules and triggers proliferation of B-cells and IgM and IL-6 production. A third type of CpG ODN has been identified, termed ODN Type C, with both high induction of INF-alpha in PDC and activation of B-cells. The sequence of CpG Type C (also called K) (i.e. ODN 2395 or M362) combines elements of both Type A and Type B and contains a central palindromic sequence with CG dinucleotides, a characteristic feature of Type A, and a TCGTCG motif at the 5' end, present in Type B CpG ODNs. Although the CpG motifs are thought to differ between mice and humans, in both species the recognition of CpG ODNs is mediated by TLR9. The optimal CpG motif in humans is GTCGTT and GACGTT for the murine sequence. However, recent evidence suggests that this sequence specificity is restricted to phosphorothioate (PS)-modified ODN and is not observed when a natural phosphodiester backbone is used. In recent years sequence requirements, specificity, signaling pathways and kinetics of the TLR9 suppression by inhibitory ODNs (iODNs) have been investigated.

Catalog Number: (102514-668)

Supplier: Adipogen

Description: AdipoR2 is a receptor for globular and full-length adiponectin, an essential hormone secreted by adipocytes that acts as an antidiabetic. AdipoR2 is probably involved in metabolic pathways that regulate lipid metabolism such as fatty acid oxidation. It mediates increased AMPK, PPAR-alpha ligand activity, fatty acid oxidation and glucose uptake by adiponectin. It is a high-affinity receptor for globular adiponectin but low-affinity receptor for full-length adiponectin. It is widely expressed.

Sale

Supplier: Adipogen

Description: PARP-1 inhibitor. Neuroprotectant. Blocks nitric oxide-induced neuronal toxicity. Potent iNOS (inducible nitric oxide synthase/NOS II) inhibitor. Stimulates homologous recombination.

Supplier: Adipogen

Description: Most commonly-used phorbol ester. Binds to and activates protein kinase C (PKC) at nM concentrations. Induces cell growth arrest through a variety of pathways including the mitogen-activated protein kinases (MAPKs), p38 and c-Jun N-terminal kinase (JNK) pathways mediated by cyclin dependent kinase (CDK) inhibitors such as p21WAF1/CIP1, p27KIP1, p15 and p16. Potent mouse skin tumor promoter. Promoter of inducible NOS (iNOS; NOS II). Apoptosis inducer. Potential effective cancer therapeutic agent. Inhibitor of anti-lipolytic activity of insulin.

Catalog Number: (102979-966)

Supplier: Adipogen

Description: LYVE-1 has been identified as a major receptor for HA (extracellular matrix glycosaminoglycan hyaluronan) on the lymph vessel wall. Like CD44, the LYVE-1 molecule binds both soluble and immobilized HA. However, unlike CD44, the LYVE-1 molecule co-localizes with HA on the luminal face of the lymph vessel wall and is completely absent from blood vessels. Hence, LYVE-1 is the first lymph-specific HA receptor to be characterized and is a uniquely powerful marker for lymph vessels themselves.

Sale

Supplier: Adipogen

Description: The cytokine Tumor necrosis factor-alpha (TNF-alpha) is secreted by activated monocytes/macrophages and T lymphocytes and has been implicated in several disease states, including rheumatoid arthritis, inflammatory bowel disease, septic shock, and osteoporosis. Monocyte/macrophage production of TNF-alpha is dependent on the mitogen-activated protein kinase p38. The compound RWJ 67657 is a potent, orally active inhibitor of MAPK and it inhibited the release of TNF-alpha from LPA stimulated human mononuclear cells with an IC(50) of 3nM, as well as the release of TNF-alpha from peripheral blood mononuclear cells treated with the T cell stimulator and superantigen staphylococcal enterotoxin B with an IC(50) value of 13nM. Also RWJ 67657 was approximately 10-fold more potent than the literature standard p38 kinase inhibitor SB 203580 in all p38 dependent in vitro systems tested and is much more specific than SB 203580 for p38 kinaes. RWJ 67657 inhibited the enzymatic activity of recombinant p38alpha and beta, with in vitro IC(50) values of 1 and 11µM respectively, but not gamma or delta, and in further in vitro test across a panel of other enzymes RWJ 67657 demonstrated no other significant activity.